Eli Other Operating Expenses from 2010 to 2024
| LLY Stock | USD 750.77 4.03 0.54% |
Other Operating Expenses | First Reported 1985-12-31 | Previous Quarter 6.1 B | Current Value 6.3 B | Quarterly Volatility 1.5 B |
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.5 M, Interest Expense of 327.9 M or Total Revenue of 35.8 B, as well as many exotic indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
Eli | Other Operating Expenses |
Latest Eli Lilly's Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Eli Lilly and over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eli Lilly. It is also known as Eli Lilly overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Eli Lilly's Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Eli Other Operating Expenses Regression Statistics
| Arithmetic Mean | 16,691,533,214 | |
| Geometric Mean | 15,383,525,811 | |
| Coefficient Of Variation | 28.20 | |
| Mean Deviation | 2,761,200,144 | |
| Median | 17,565,000,000 | |
| Standard Deviation | 4,706,968,689 | |
| Sample Variance | 22155554.2T | |
| Range | 21.3B | |
| R-Value | 0.44 | |
| Mean Square Error | 19158624.9T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | 467,193,884 | |
| Total Sum of Squares | 310177759.3T |
Eli Other Operating Expenses History
About Eli Lilly Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Eli Lilly income statement, its balance sheet, and the statement of cash flows. Eli Lilly investors use historical funamental indicators, such as Eli Lilly's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Eli Lilly investors may use each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eli Lilly Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 23.8 B | 12 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Eli Lilly Correlation against competitors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.82 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.